This categorization was adopted to investigate the potential prognostic implications of lower Ki‐67 expression levels in our patient population, acknowledging the variability and lack of consensus on standardized cutoff values in breast cancer studies [40]. This evidence concerns the gene MKI67 and breast cancer.